The purpose of this double-masked, randomized, controlled study is to assess the safety and
ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops
compared to Timolol maleate 0.5% after 28 treatment days in patients with elevated
intraocular pressure.